

## And it's a wrap for 2024



2024 was a challenging year for healthcare which came to a tumultuous end with negative sentiment around PBMs and Insurance companies and major readouts coming below what were inflated expectations.

**Overall**, this newsflow has depressed valuations further, but fundamentals remain intact and strong, with above-market earnings growth expectations. We therefore see 2025 as an attractive entry point for the sector.

### Negative news for PBMs/Insurance

The healthcare insurance and pharmacy benefits segment was hit by a storm of negative news during December.

First was the tragic murder of UnitedHealth CEO, which in itself would not have had a major impact to the company's fundamentals. However the event stirred up a lot of debate and negative sentiment around health insurance claim denial practices.

This was followed by a bipartisan bill targeting Pharmacy Benefit Managers (PBMs). PBMs are typically hired by insurance companies to negotiate discounts with drug manufacturers based on bulk purchasing agreements. PBMs can be integrated in companies which also operate pharmacies or within insurance companies

The objective of the bill is to prohibit joint ownership of PBMs and pharmacies, as this allegedly leads to increased costs. While this bill is still far from being signed into law, its announced contributed to strong negative sentiment for the group.

Later in the month, Trump singled out "middlemen" as responsible for the costs in US healthcare. This was widely understood as referring to PBMs and drug distributors.

Finally, House Republicans opened an investigation into CVS's PBM business regarding alleged violations of antitrust laws.

While we expect that the impact of these events on future earnings will be low. The bill still has a lot of wood to chop before becoming law, and Trump's comment were vague and far from any kind of policy. All nonetheless contributed significantly to major negative sentiment for the group over the past month.

### Major trial readouts

Data of two widely anticipated clinical trials was released late in December:

The first was Vertex' suzetrigine phase 2 trial to treat sciatica pain. This was highly anticipated as there is a high unmet need for non-opioid pain treatment. The data was disappointing due to an unexpectedly high placebo response, but the drug is active. Vertex plans to proceed with a pivotal Phase 3 trial.

Novo Nordisk reported long-awaited CagriSema phase 3 data in overweight or obese adults. The treatment achieved 22.7% weight loss, falling short of market expectations of 25%. Novo is planning an additional phase III obesity trial in 2025 and is on track to file for approval by the end of 2025.

### Performance Overview

	1M	3M	YTD	12M
Healthcare	-6.0%	-13.9%	1.1%	4.9%
Medtech	-4.0%	-2.8%	8.6%	19.8%
Services	-13.5%	-16.2%	-7.6%	-7.7%
Pharma	-5.1%	-18.2%	2.2%	6.8%
Biotech	-4.6%	-14.2%	-0.1%	3.1%
Tools	-2.9%	-12.0%	-1.9%	-5.5%
World	-2.8%	1.7%	18.7%	46.6%

#### Top 5 last month

1	Teva	31%	Earnings
2	Galderma	9%	FDA drug approval
3	Neurocrine	8%	FDA drug approval
4	Getinge	5%	No news
5	Fresenius Medical	4%	DAX inclusion

#### Bottom 5 last month

1	CVS	-25%	Investigation + PBM bill
2	Carl Zeiss	-21%	Earnings, guidance cut
3	Novo Nordisk	-19%	CagriSema weight loss data
4	Cigna	-18%	PBM bill
5	Ramsay Health	-17%	No news

Source: Bloomberg Finance L.P., Kieger

## Kieger Healthcare Team



**Dr Maria Specogna**

Lead Manager,  
Sustainable Healthcare Fund



**Raphael Oesch, CFA**

Lead Manager,  
Blue Chip Healthcare Fund



**Flavio Mancino, CFA**

Research Analyst




**Guy Bettschart, CFA, CAIA**

Research Analyst



**For a comprehensive overview of our investment strategies please contact us:**

 +41 44 444 18 44

 [www.kieger.com](http://www.kieger.com)

 <mailto:info@kieger.com?subject=Contact>  
[Kieger\\_\\_\\_\\_\\_Monthly\\_\\_\\_\\_\\_Healthcare](mailto:Kieger_____Monthly_____Healthcare)  
[Commentaryinfo@kieger.com](mailto:Commentaryinfo@kieger.com)



<https://goo.gl/maps/r5NNVHw68z3gANTn7Dianas>  
trasse 5,  
8002 Zürich

<https://www.linkedin.com/company/kieger->



## **Kieger is a proud member/signatory of:**

This document has been issued through Kieger AG and is for distribution only under such circumstances as may be permitted by applicable law. This document is for information purposes only and does not constitute an offer. Past performance is not a reliable indicator of future results. The details and opinions contained in this document are provided by Kieger without any guarantee or warranty and are for the recipient's personal use only. All information and opinions contained in this document are subject to change without notice. This document may contain statements that constitute "forward looking statements". A number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. Data source: Statestreet / Factset

## **Important Legal Information**

This is a marketing communication. The information contained therein is intended only for information purposes and does not represent an offer to purchase or sell financial instruments. The source of the information is considered reliable; however, the accuracy or completeness of such information is not guaranteed. The information is subject to change from time to time without notice. This information neither represents any investment / legal / tax advice, or any recommendation. The Agent (as defined below) points out that every investment decision should be made after consulting an advisor.

Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units.

Please refer to and read carefully the Prospectus of Kieger UCITS Fund (the "Fund") and the Key Investor Information Document ("KIID") of the Kieger UCITS Fund - Kieger Sustainable Healthcare Fund and the Kieger UCITS Fund - Kieger Impact Healthcare Fund in their latest versions before making any final investment decisions. These documents can be obtained in English from the website <https://kieger.com/ucits> or any agents as further described below.

A decision to invest in the sub-fund should take into account all the characteristics or objectives of the sub-fund as disclosed in the Prospectus.

A summary of the investor rights is available in English at <https://kieger.com/regulatory-disclosures>. Further information about the sustainability-related aspects of the Fund is available at <https://kieger.com/regulatory-disclosures>.

The fund is marketing in multiple member states of European Union and Switzerland. The management company reserves the right to terminate the arrangements made for the marketing of the Fund in accordance with Article 93a of the Directive 2009/65/EC.

### **Information for Swiss Investors:**

This is an advertising document. The state of the origin of the fund is Luxembourg. In Switzerland, the representative is Acolin Fund Services AG, Maintower, Thurgauerstrasse 36/38, CH-8050 Zurich, Switzerland, whilst the paying agent is Banque Cantonale de Genève, 17, Quai de l'Île, CH-1204 Geneva. The prospectus, the key information documents or the key investor information documents, the articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative.

### **Information for German Investors:**

The Fund's Facilities agent in Germany is Acolin Europe AG, with the registered office at Line-Eid-Straße 6, 78467 Konstanz. The Prospectus (in English) and the KIID (in German), may be obtained free of charge at the registered office of the Facilities agent, or electronically by Email [facilityagent@acolin.com](mailto:facilityagent@acolin.com), or by using the contact form at <https://acolin.com/services/facilities-agency-services>.

### **Information for Austrian Investors:**

The Facility agent according to EU Directive 2019/1160 Article 92, as well as tax representative in Austria, is Erste bank der oesterreichischen Sparkassen AG, with the registered office at Am Belvedere 1, A-1100 Vienna. The Prospectus (in English) and the KIIDs (in German) may be obtained free of charge at the registered office of the Facility agent, or electronically by Email [foreignfunds0540@erstebank.at](mailto:foreignfunds0540@erstebank.at).

### **Marketing in the European Union:**

The issuer of this marketing communication in Europe (excluding Switzerland) is Kieger Capital Partners S.à.r.l. Kieger Capital Partners S.à.r.l. ("Tied Agent") is a tied agent within the meaning of Article 29 (3) of Directive 2014/65/EU ("MiFID II") as implemented in the respective national legislation) of Acolin Europe AG, which is authorised and regulated by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). The Tied Agent is entered in the public register of tied agents held by CSSF in his homecountry Luxembourg.

Within the scope of providing financial services ("investment brokerage" within the meaning of Annex I A (1) MiFID II as implemented in the respective national legislation by promotion of the potential investor's willingness to enter into a transaction but excluding the reception and transmission of orders in relation to one or more financial instruments), the Tied Agent acts exclusively on behalf and for the account of Acolin Europe AG and undertakes to exclusively distribute the Kieger UCITS funds.

The information provided by the Tied Agent is intended for informational purposes only and does not represent an offer to purchase or sell financial instruments. All information is provided without any guarantee. This information neither represents any investment / legal / tax advice, nor any recommendation. The Agent points out that every investment decision should be made after consulting an advisor. The information is intended exclusively for professional clients within the meaning of Annex II MiFID II.

The information provided may not be copied or further distributed to third parties without the prior consent of Acolin Europe AG. The information may not be given to persons or companies that do not have their ordinary residence or domicile in the countries in which Acolin Europe AG is authorized to provide financial services. In particular, the information may not be made available to US citizens or persons residing in the USA. This document may not be copied or used for other purposes, nor may the content of the document be forwarded to third parties.